Calton & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.33M | Sell |
2,534
-264
| -9% | -$268K | 0.33% | 72 |
|
|
2025
Q4 | $3.01M | Sell |
2,798
-259
| -8% | -$248K | 0.44% | 50 |
|
|
2025
Q3 | $2.33M | Buy |
3,057
+845
| +38% | +$629K | 0.35% | 63 |
|
|
2025
Q2 | $1.72M | Sell |
2,212
-320
| -13% | -$249K | 0.3% | 70 |
|
|
2025
Q1 | $2.09M | Buy |
2,532
+1,521
| +150% | +$1.27M | 0.48% | 45 |
|
|
2024
Q4 | $781K | Sell |
1,011
-825
| -45% | -$683K | 0.35% | 70 |
|
|
2024
Q3 | $1.63M | Buy |
1,836
+801
| +77% | +$720K | 0.62% | 39 |
|
|
2024
Q2 | $937K | Buy |
1,035
+4
| +0.4% | +$3.2K | 0.47% | 52 |
|
|
2024
Q1 | $802K | Sell |
1,031
-261
| -20% | -$186K | 0.39% | 62 |
|
|
2023
Q4 | $753K | Buy |
+1,292
| New | +$754K | 0.3% | 79 |
|
|
2023
Q3 | – | Sell |
-1,320
| Closed | -$619K | – | 197 |
|
|
2023
Q2 | $619K | Buy |
1,320
+131
| +11% | +$54.9K | 0.29% | 86 |
|
|
2023
Q1 | $408K | Sell |
1,189
-783
| -40% | -$264K | 0.19% | 116 |
|
|
2022
Q4 | $721K | Buy |
1,972
+209
| +12% | +$74.1K | 0.28% | 84 |
|
|
2022
Q3 | $570K | Hold |
1,763
| – | – | 0.33% | 76 |
|
|
2022
Q2 | $571K | Sell |
1,763
-256
| -13% | -$76.8K | 0.32% | 84 |
|
|
2022
Q1 | $578K | Sell |
2,019
-78
| -4% | -$20.1K | 0.17% | 144 |
|
|
2021
Q4 | $579K | Sell |
2,097
-386
| -16% | -$97.9K | 0.15% | 163 |
|
|
2021
Q3 | $573K | Sell |
2,483
-206
| -8% | -$50.8K | 0.13% | 185 |
|
|
2021
Q2 | $618K | Buy |
2,689
+1
| +0% | +$201 | 0.12% | 173 |
|
|
2021
Q1 | $502K | Sell |
2,688
-386
| -13% | -$75.5K | 0.1% | 184 |
|
|
2020
Q4 | $519K | Sell |
3,074
-70
| -2% | -$10.5K | 0.09% | 176 |
|
|
2020
Q3 | $465K | Buy |
3,144
+171
| +6% | +$26.5K | 0.1% | 163 |
|
|
2020
Q2 | $488K | Sell |
2,973
-213
| -7% | -$32.7K | 0.11% | 153 |
|
|
2020
Q1 | $442K | Buy |
3,186
+516
| +19% | +$70.9K | 0.11% | 149 |
|
|
2019
Q4 | $351K | Buy |
2,670
+505
| +23% | +$58.5K | 0.07% | 226 |
|
|
2019
Q3 | $242K | Buy |
2,165
+262
| +14% | +$29.2K | 0.05% | 276 |
|
|
2019
Q2 | $211K | Sell |
1,903
-3,860
| -67% | -$455K | 0.06% | 252 |
|
|
2019
Q1 | $748K | Buy |
5,763
+185
| +3% | +$22.5K | 0.23% | 80 |
|
|
2018
Q4 | $646K | Buy |
5,578
+920
| +20% | +$103K | 0.24% | 86 |
|
|
2018
Q3 | $500K | Buy |
4,658
+2,379
| +104% | +$238K | 0.15% | 118 |
|
|
2018
Q2 | $233K | Buy |
+2,279
| New | +$187K | 0.07% | 241 |
|
|
2018
Q1 | – | Sell |
-2,818
| Closed | -$237K | – | 884 |
|
|
2017
Q4 | $237K | Buy |
+2,818
| New | +$240K | 0.06% | 299 |
|
Other funds holding LLY
VCM
VPM
Calton & Associates's LLY Position: Q1 2026 in Review
Calton & Associates reduced its Eli Lilly (LLY) stake by 9.4% in Q1 2026, selling an estimated $268K and leaving 2,534 shares worth $2.33M. The position accounts for 0.33% of the portfolio, ranked #72.
Calton & Associates first reported a position in LLY in Q4 2017 and has held it in 32 quarters since. The position peaked at $3.01M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Calton & Associates held 2,534 shares of Eli Lilly worth $2.33M as of Q1 2026.
- Calton & Associates sold 264 Eli Lilly shares in Q1 2026, an estimated $268K.
- Eli Lilly made up 0.33% of Calton & Associates's portfolio in Q1 2026, its #72 holding.
- Calton & Associates first reported a position in Eli Lilly in Q4 2017 and has held it in 32 quarters since.
- Calton & Associates's Eli Lilly position peaked at $3.01M in Q4 2025.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.